Novartis: Carcinoma trials

The registry lists 19 Carcinoma studies with Novartis as lead sponsor. 0 are open to participants now and 12 have results posted.

Phase 2 13Phase 3 5Phase 4 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.CompletedNCT05110196Phase 4Results posted
• Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line TherapyTerminatedNCT04816214Phase 3Results posted
• Phase III Study Evaluating Efficacy and Safety of Canakinumab in Combination With Docetaxel in Adult Subjects With Non-small Cell Lung Cancers as a Second or Third Line TherapyTerminatedNCT03626545Phase 3Results posted
• A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial CancerCompletedNCT01379534Phase 2Results posted
• Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.CompletedNCT01035229Phase 3Results posted
• Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneTerminatedNCT00968968Phase 3Results posted
• Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney CancerCompletedNCT00719264Phase 2Results posted
• RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in EuropeCompletedNCT00688753Phase 2Results posted
• RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in EuropeCompletedNCT00688623Phase 2Results posted
• Everolimus and Octreotide in Patients With Advanced Carcinoid TumorCompletedNCT00412061Phase 3Results posted
• Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyCompletedNCT00363051Phase 2Results posted
• Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal CarcinomatosisCompletedNCT00332696Phase 2Results posted
• Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)WithdrawnNCT03240393Phase 2
• A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma PatientsCompletedNCT01576380Phase 2
• EPO906 in Carcinoid and Other Neuroendocrine TumorsCompletedNCT00050349Phase 2
• EPO906 Therapy in Patients With Advanced Kidney CancerCompletedNCT00035243Phase 2
• EPO906 Therapy in Patients With Prostate CancerCompletedNCT00035113Phase 2
• EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal CancerCompletedNCT00035100Phase 2
• EPO906 Therapy in Patients With Advanced Colorectal CancerCompletedNCT00035087Phase 2